Joseph Walter Vazzano Buys 5,608 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) CFO Joseph Walter Vazzano purchased 5,608 shares of the business’s stock in a transaction on Thursday, April 25th. The stock was purchased at an average price of $3.14 per share, with a total value of $17,609.12. Following the purchase, the chief financial officer now owns 233,868 shares of the company’s stock, valued at $734,345.52. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Abeona Therapeutics Price Performance

ABEO stock opened at $3.26 on Friday. Abeona Therapeutics Inc has a one year low of $2.83 and a one year high of $9.01. The stock has a market cap of $89.16 million, a price-to-earnings ratio of -1.26 and a beta of 1.49. The company has a fifty day moving average price of $7.23 and a two-hundred day moving average price of $5.60.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13). Research analysts anticipate that Abeona Therapeutics Inc will post -2.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Abeona Therapeutics

Hedge funds have recently bought and sold shares of the stock. Simplex Trading LLC grew its position in shares of Abeona Therapeutics by 1,889.9% in the third quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 13,418 shares during the last quarter. Barclays PLC boosted its stake in Abeona Therapeutics by 100.0% in the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after purchasing an additional 185,638 shares during the period. Citigroup Inc. grew its holdings in Abeona Therapeutics by 125.0% in the 3rd quarter. Citigroup Inc. now owns 450,000 shares of the biopharmaceutical company’s stock valued at $1,894,000 after buying an additional 250,000 shares in the last quarter. AIGH Capital Management LLC increased its position in Abeona Therapeutics by 77.7% during the 3rd quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock worth $4,779,000 after buying an additional 496,278 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Abeona Therapeutics during the third quarter worth $648,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ABEO shares. StockNews.com downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 23rd. Cantor Fitzgerald restated an “overweight” rating and issued a $36.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday, April 23rd.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.